GENTICEL - Vaccines for HPV infected women

Genticel develops therapeutic vaccines for women already infected by the human papillomavirus (HPV) before high grade lesions or cervical cancer occur.

The World Health Organization estimated recently that world-wide, 300 million women are carriers of HPV.

Of these, about 93 million women are infected with HPV16 and/or HPV18 types, two HPV types that cause most cancers.

5 million of these women will develop dangerous pre-cancer. Despite prevention and treatment schemes, 350,000 HPV 16+ or HPV18+ patients are still diagnosed with cervical cancer each year.

The company focuses its efforts exclusively on preventing progression of HPV-originating diseases. This is made possible through Genticel's unique therapeutic vaccine platform.